ANGPTL3 and metabolic dysfunction-associated steatotic liver disease: This review explores current and emerging TG-lowering therapies, including fibrates, omega-3 fatty acids, pemafibrate, and novel agents such as pegozafermin (an FGF21 analog), and APOC3 and angiopoietin-like protein 3 (ANGPTL3) inhibitors, in the context of hepatic steatosis and MASLD.